BRIEF

on InfusionPoints, LLC

InfusionPoints XBU40 Accelerates DoD IL4 Provisional Authorization for CoachMePlus and TIAG

InfusionPoints, LLC has announced the successful leveraging of its XBU40 platform to achieve a DoD IL4 Provisional Authorization (PA) for the CoachMePlus and TIAG Warrior Performance Platform (WP2). This development supports the U.S. Army's Holistic Health and Fitness Management System (H2FMS). The XBU40 platform utilizes cloud native services on AWS, combined with InfusionPoints' VNSOC360° managed services, to streamline the authorization process while minimizing preparation time and costs.

Senior Army leaders had sought a solution to consolidate Soldier health and fitness data. This led to the selection of the WP2 platform by the Army Applications Laboratory. WP2 aims to help Soldiers meet their health and fitness goals, while providing data to enhance overall readiness and well-being.

Teo Balbach, CEO of CoachMePlus, expressed enthusiasm about using data-driven decisions to improve Soldier training and performance. CoachMePlus and TIAG, both requiring a secure DoD-compliant platform, faced challenges such as team size and unfamiliarity with the authorization process.

Through the AWS Global Security and Compliance Acceleration (GSCA) program, InfusionPoints facilitated the integration of WP2 into the AWS GovCloud PaaS, XBU40. This expedited the time to authorization, resulting in both a DoD IL4 PA from DISA and an Interim Authority to Test (IATT) from the Army in March 2024.

Jackson Gorman, XBU40 Product Lead, highlighted that while typical DoD PA timelines span eighteen to twenty-four months, their team completed the process in fourteen months.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all InfusionPoints, LLC news